MA38606A1 - Composition pharmaceutique et son utilisation, ainsi que schéma d'emploi de cette composition pharmaceutique pour la contraception à la demande - Google Patents

Composition pharmaceutique et son utilisation, ainsi que schéma d'emploi de cette composition pharmaceutique pour la contraception à la demande

Info

Publication number
MA38606A1
MA38606A1 MA38606A MA38606A MA38606A1 MA 38606 A1 MA38606 A1 MA 38606A1 MA 38606 A MA38606 A MA 38606A MA 38606 A MA38606 A MA 38606A MA 38606 A1 MA38606 A1 MA 38606A1
Authority
MA
Morocco
Prior art keywords
pharmaceutical composition
demand
well
contraception
combination
Prior art date
Application number
MA38606A
Other languages
English (en)
Inventor
Andrea Rotgeri
Anne Mengel
Bernd Buchmann
Laak Antonius Ter
Bernhard Lindenthal
Peter Serno
Ulrike Fuhrmann
Nico Bräuer
Ulrike Röhn
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of MA38606A1 publication Critical patent/MA38606A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne une composition pharmaceutique destinée à la contraception à la demande non hormonale, ainsi que des procédés de préparation de cette composition pharmaceutique, qui contient des 2h-indazoles en tant que nouveaux antagonistes des récepteurs ep2 en combinaison avec des inhibiteurs de cox. Un autre objet de l'invention est un procédé de contraception féminine contrôlée non hormonale à la demande, consistant à prendre à la demande, avant un rapport sexuel prévu, une composition pharmaceutique qui contient des antagonistes des récepteurs ep2 en combinaison avec des inhibiteurs de cox.
MA38606A 2013-05-23 2014-05-16 Composition pharmaceutique et son utilisation, ainsi que schéma d'emploi de cette composition pharmaceutique pour la contraception à la demande MA38606A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13169029 2013-05-23
PCT/EP2014/060103 WO2014187744A1 (fr) 2013-05-23 2014-05-16 Composition pharmaceutique et son utilisation, ainsi que schéma d'emploi de cette composition pharmaceutique pour la contraception à la demande

Publications (1)

Publication Number Publication Date
MA38606A1 true MA38606A1 (fr) 2017-03-31

Family

ID=48463871

Family Applications (1)

Application Number Title Priority Date Filing Date
MA38606A MA38606A1 (fr) 2013-05-23 2014-05-16 Composition pharmaceutique et son utilisation, ainsi que schéma d'emploi de cette composition pharmaceutique pour la contraception à la demande

Country Status (20)

Country Link
US (1) US9655887B2 (fr)
EP (1) EP2999469A1 (fr)
JP (1) JP6370887B2 (fr)
KR (1) KR20160014598A (fr)
CN (1) CN105451737B (fr)
AP (1) AP2015008855A0 (fr)
AR (1) AR096386A1 (fr)
AU (1) AU2014270596A1 (fr)
BR (1) BR112015029214A2 (fr)
CA (1) CA2913085A1 (fr)
CL (1) CL2015003434A1 (fr)
EA (1) EA201592207A1 (fr)
HK (1) HK1217640A1 (fr)
MA (1) MA38606A1 (fr)
MX (1) MX2015016121A (fr)
PH (1) PH12015502598A1 (fr)
TN (1) TN2015000511A1 (fr)
TW (1) TW201522325A (fr)
UY (1) UY35584A (fr)
WO (1) WO2014187744A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112313208B (zh) 2018-04-17 2024-04-19 泰普斯特医疗公司 双环羧酰胺及其使用方法
CN110215447A (zh) * 2019-06-14 2019-09-10 上海市计划生育科学研究所 甲芬那酸在避孕药物中的应用及其制备的杀精避孕药物

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ295365A (en) 1994-10-24 1999-07-29 Schering Ag Competitive progesterone antagonists for regulating female fertility as required
HU227198B1 (en) 2001-11-27 2010-10-28 Richter Gedeon Nyrt Pharmaceutical composition for emergency contraception containing levonorgestrel
US20040058975A1 (en) * 2002-06-26 2004-03-25 Schering Ag Method for fertility control
EP1866292B1 (fr) 2005-03-31 2010-12-15 Auckland Uniservices Limited Oxydes de 1,2,4-triazine tricycliques et leurs compositions a usage therapeutique dans les traitements anticancereux
DE102005050729A1 (de) 2005-10-19 2007-04-26 Schering Ag Verfahren zur präventiven bedarfsweisen hormonalen Kontrazeption
BRPI0707718A2 (pt) 2006-02-10 2011-05-10 Summit Corp Plc uso de um composto
WO2008070599A1 (fr) 2006-12-05 2008-06-12 Chung-Ming Sun Composés d'indazole
US20100256109A1 (en) * 2007-11-15 2010-10-07 Sarah Elizabeth Skerratt Azetidines As EP2 Antagonists
WO2010119029A1 (fr) 2009-04-14 2010-10-21 Laboratoire Hra-Pharma Methode de contraception à la demande
US20120129825A1 (en) 2009-04-14 2012-05-24 Andre Ulmann Method for on-demand contraception using levonorgestrel or norgestrel
AU2010239188B2 (en) 2009-04-22 2016-03-31 Janssen Pharmaceutica Nv Azetidinyl diamides as monoacylglycerol lipase inhibitors
CN102458386B (zh) 2009-06-23 2016-04-06 拜耳知识产权有限责任公司 用于紧急避孕的药物组合物
DE102009049662A1 (de) * 2009-10-13 2011-04-14 Bayer Schering Pharma Aktiengesellschaft 2,5-Disubstituierte 2H-Indazole als EP2-Rezeptor-Antagonisten
US8426392B2 (en) 2009-12-09 2013-04-23 Laboratoire Hra-Pharma Method for providing emergency contraception
US20130045959A1 (en) 2010-02-01 2013-02-21 Andre Ulmann Method for late post coital contraception using ulipristal acetate
TW201326154A (zh) * 2011-11-28 2013-07-01 拜耳知識產權公司 作為ｅｐ２受體拮抗劑之新穎２ｈ－吲唑

Also Published As

Publication number Publication date
AP2015008855A0 (en) 2015-11-30
UY35584A (es) 2014-12-31
CN105451737B (zh) 2018-04-10
WO2014187744A1 (fr) 2014-11-27
TN2015000511A1 (en) 2017-04-06
AU2014270596A1 (en) 2015-12-03
US20160089364A1 (en) 2016-03-31
JP6370887B2 (ja) 2018-08-08
HK1217640A1 (zh) 2017-01-20
EA201592207A1 (ru) 2016-06-30
CN105451737A (zh) 2016-03-30
AR096386A1 (es) 2015-12-30
PH12015502598A1 (en) 2016-02-29
CL2015003434A1 (es) 2016-07-22
US9655887B2 (en) 2017-05-23
EP2999469A1 (fr) 2016-03-30
TW201522325A (zh) 2015-06-16
BR112015029214A2 (pt) 2017-07-25
JP2016518456A (ja) 2016-06-23
MX2015016121A (es) 2016-03-31
KR20160014598A (ko) 2016-02-11
CA2913085A1 (fr) 2014-11-27

Similar Documents

Publication Publication Date Title
MX2024011839A (es) Compuetos heterociclicos utiles en el tratamiento de enfermedades.
EP3291765A4 (fr) Procédés d'administration d'un agent à l'oeil
EP3714275A4 (fr) Réduction de la présentation d'épitope de jonction pour des néo-antigènes
SV2018005771A (es) Derivados de piridiniltriazol sustituidos con amida y usos de estos
EP3755311A4 (fr) Indane-amines utiles en tant qu'antagonistes de pd-l1
EP3322415A4 (fr) Dérivés d'arylhérétoaryl urée en tant que modulateurs du récepteur sérotoninergique 5-ht2a utiles pour la prophylaxie et le traitement d'hallucinations associées à une maladie neurodégénérative
TN2019000099A1 (fr) Anticorps anti-lag-3 et compositions
MA40576B1 (fr) Anticorps et immunoconjugués anti-her2
MA40682A (fr) Anticorps anti-ox40 et procédés d'utilisation correspondants
EP3371972A4 (fr) Étalonnage d'affichage dynamique basé sur un suivi oculaire
MA51815A (fr) Méthodes de traitement ou de prévention de migraines avec anticorps contra le receptor de cgrp
EP3380970A4 (fr) Nouveaux dérivés azolés comme agoniste du récepteur de l'apéline
EP3325080A4 (fr) Procédés pour l'administration améliorée de principes actifs à des tumeurs
EA201891376A1 (ru) Бензотиофеновые селективные блокаторы эстрогеновых рецепторов
PH12016502167A1 (en) Hdl theraphy markers
MA39171A1 (fr) Dérivés d'hydroxy formamide et leur utilisation
EP3402771A4 (fr) Procédé pour la préparation d'oléfine contenant du fluor
EP3452491A4 (fr) Profilage quantitatif de métabolites de la progestérone pour la prédiction de l'accouchement prématuré spontané
MX2018006802A (es) Derivados de fenilo como agonistas del receptor de canabinoides 2.
AR096338A1 (es) (ciano-dimetil-metil)-isoxazoles y -[1,3,4]tiadiazoles
MA40366A (fr) Dérivés de tétrahydroquinoline à titre d'inhibiteurs des bromodomaines
EP3313380A4 (fr) Composition pour l'administration d'agents actifs à un animal
IT201600078872A1 (it) Olio e dispositivo per l'igiene dell'area oculare e perioculare
EP3337811A4 (fr) Nouveaux composés utilisés en tant que modulateurs allostériques positifs pour l'érythropoïétine et le récepteur de l'érythropoïétine pour le traitement de maladies liées à une déficience en érythropoïétine
MA39411A (fr) Synthèse de l'énantiomère de la progestérone et ses intermédiaires